CVS Health Announces Major Plan to Split into Two Public Companies by 1H 2028

Executive Summary

On November 4, 2026, CVS Health Corporation (NYSE: CVS) filed a Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure) announcing a transformative board-approved strategic decision to separate into two independent, publicly traded companies. The separation is structured to be tax-free for U.S. federal income tax purposes and is targeted for completion in the first half of 2028.

Business Structure & Asset Division

The planned separation will divide CVS Health’s integrated healthcare portfolio into two distinct standalone entities:

1. Healthcare Solutions Company (to retain the name CVS Health in the interim):

   • Core Assets: Aetna health benefits, CVS Caremark pharmacy benefit management (PBM), CVS Specialty pharmacy, Oak Street Health primary care, and Signify Health in-home care delivery.
   • Leadership: David Joyner, currently Chairman and CEO of CVS Health, will serve as Chairman and CEO.
   • Strategic Focus: Integrated care delivery, payer solutions, risk-bearing value-based care, and comprehensive health benefits.

2. Retail & Community Healthcare Company (to be named CVS Pharmacy):

   • Core Assets: Approximately 9,000 retail pharmacies, mail-order pharmacy operations, MinuteClinic (including virtual care), and the Health100 AI/technology services platform.
   • Leadership: Prem Shah, currently Group President of CVS Health, will serve as CEO.
   • Strategic Focus: Front-line consumer healthcare access, clinical retail services, payer-agnostic partnerships, and dispensing operations.

Key Transaction Terms & Timeline

• Tax Treatment: Intended to qualify as a tax-free separation under U.S. federal income tax rules for both the company and its shareholders.
• Ownership: Existing CVS Health shareholders will receive shares in both independent entities upon closing.
• Balance Sheet & Capital Allocation: Both companies are expected to target solid investment-grade credit ratings with balance sheet capacity to pursue independent capital allocation, capital expenditure, and dividend programs.
• Target Closing: First half of 2028, subject to final board approval, Form 10 registration effectiveness with the SEC, and customary tax rulings.
• Advisors: Goldman Sachs & Co. LLC (lead financial/strategic advisor), Consello (financial/strategic advisor), and Wachtell, Lipton, Rosen & Katz (legal counsel).

Market & Strategic Implications

• Unwinding the Conglomerate Discount: The separation represents a major pivot from the vertically integrated healthcare model CVS pioneered with its $69B acquisition of Aetna in 2018 and subsequent provider acquisitions (Signify Health and Oak Street Health in 2023). By separating the retail dispensing footprint from the payer/PBM/provider arm, each entity gains operational focus and the ability to partner across competing industry players.
• Payer/Pharmacy Decoupling: Standalone CVS Pharmacy will have greater flexibility to partner with non-Aetna commercial payers and competing PBMs, while the healthcare solutions business can streamline medical cost management and value-based risk operations.